Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

This study is to evaluate the efficacy and safety of mirabegron in patients with intracerebral hemorrhage based on standard therapy

Inclusion criteria

• Male or female patients aged above 18 years old.
• The volume of the hematoma is 5-30 ml (including the cerebral cortex; Putamen, thalamus, caudate nucleus and related deep tracts; Cerebellar hemorrhage), which determined by CT scan.
• The onset of cerebral hemorrhage symptoms or the time from last normal to detection is not more than 72 hours.
• Patients with Glasgow Coma Scale (GCS) score ≥6 and < 12.
• Before the onset of the disease, function was independent and mRS score<1.
• Able and willing to sign written informed consent and comply with the requirements of the research protocol.

Exclusion criteria

• Multifocal cerebral hemorrhage, brain stem hemorrhage, or ventricular hemorrhage.
• Secondary cerebral hemorrhage caused by aneurysm, brain tumor, arteriovenous malformation, thrombocytopenia, coagulation disorder, traumatic brain injury, etc.
• Patients who require hematoma removal surgery or other emergency surgical interventions (such as decompressive craniectomy), or who are critically ill and close to death.
• Patients who interfere with drug use due to nausea or vomiting.
• Combined with the following conditions that preclude participation in the study due to other systemic diseases: Severe hepatic or renal impairment, atrial fibrillation or tachycardia, pulmonary infection, severe urinary tract infection, severe urinary tract obstruction, medically uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg), pregnant and lactating women, and a history of malignant tumors within 5 years.